Compounds > ns3694
Page last updated: 2024-11-12

ns3694

Description

NS3694: an apoptosome inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10109069
CHEMBL ID154696
CHEBI ID92474
SCHEMBL ID3961213
MeSH IDM000597498

Synonyms (28)

Synonym
BRD-K26979635-001-01-1
ns3694, >=98%, powder
HSCI1_000148
NCGC00165849-01
ns3694
apoptosis inhibitor ii, ns3694
4-chloro-2-[[3-(trifluoromethyl)phenyl]carbamoylamino]benzoic acid
4-chloro-2-(3-(3-(trifluoromethyl)phenyl)ureido)benzoic acid
bdbm50137149
4-chloro-2-[3-(3-trifluoromethyl-phenyl)-ureido]-benzoic acid
CHEMBL154696 ,
426834-38-0
4-chloro-2-[3-(3-trifluoromethyl-phenyl)-ureido]benzoic acid
SCHEMBL3961213
ns 3694
DTXSID00435797
CHEBI:92474
gncztzcpxfdpli-uhfffaoysa-n
Q27164210
4-chloro-2-[[oxo-[3-(trifluoromethyl)anilino]methyl]amino]benzoic acid
4-chloro-2-[3-(3-trifluoromethylphenyl)ureido]benzoic acid
apoptosis inhibitor ii
MS-25646
BSA83438
HY-108356
CS-0028441
E98648
AKOS040744983
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency22.38720.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, kainate 1Homo sapiens (human)IC50 (µMol)5.00000.07702.64425.0000AID282629; AID93246
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
nervous system developmentGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
central nervous system developmentGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
monoatomic ion transmembrane transportGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
glutamate-gated receptor activityGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
kainate selective glutamate receptor activityGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
intracellular membrane-bounded organelleGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
kainate selective glutamate receptor complexGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, kainate 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID93246In vitro inhibitory activity against human ionotropic glutamate receptor ionotropic kainate 1 (GluR-5) expressed in HEK293 cells.2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5.
AID282629Antagonist activity at human homomeric GluR5 expressed in HEK293 cells assessed as inhibition of intracellular calcium concentration by FLIPR assay2004Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27
Bioisosteric modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.74 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
tiletamine hydrochloride
Cyclohexanones: Cyclohexane ring substituted by one or more ketones in any position.. cyclohexanones : Any alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.		2.1710
ns 1608
NS 1608: a BK(Ca) channel opener		2.0210ureas
fibrin
Fibrin: A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.		2.0810peptide
2,2'-methylenebis(1,3-cyclohexanedione)
2,2'-methylenebis(1,3-cyclohexanedione): an inhibitor of apoptosis (programmed cell death). apoptosis inhibitor : Any substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.		2.1710beta-diketone
ns 1652
NS 1652: an anion conductance inhibitor; structure in first source		2.0110
ConditionIndicatedRelationship StrengthStudiesTrials
Catatonic Rigidity
[description not available]		02.0110
Muscle Rigidity
Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73)		02.0110
Degenerative Disc Disease
[description not available]		02.9710
Back Ache
[description not available]		02.9710
Calcification, Pathologic
[description not available]		02.9710
Back Pain
Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.		02.9710
Calcinosis
Pathologic deposition of calcium salts in tissues.		02.9710
Intervertebral Disc Degeneration
Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.		02.9710
chemdatabank.com